FDA OKs experimental drug therapy for breast cancer

The FDA has approved Savient Pharmaceuticals' experimental drug therapy for breast cancer. Savient said that Soltamox is the first oral liquid form of tamoxifen. It has already been approved in several European countries. Savient expects to line up a marketing partner in early 2006.

- read this AP report for more information

Suggested Articles

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.

Getting lurbinectedin on the fast track tees the partners up to learn whether the FDA will approve the drug by mid-August.